Niktimvo
Drug Cgvhd
NDC 50881-034-12
General payments
$7,342
Research payments
$1,007,066
Through program year 2025, $7,342 in general payments and $1,007,066 in research payments were reported against Niktimvo (Cgvhd).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $7,342 | 29 |
| 2025 | Research | $1,007,066 | 44 |
Breakdown
The top 5 of 28 recipients; each share is of general payments naming this product in 2025.
The top 5 of 9 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
29 general · 44 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.